左主干暨冠状动脉分叉病变峰会，CBS2019 - CBS 2019 - LEFT MAIN & CORONARY BIFURCATION SUMMIT

CBS 2019

CBSMD教育中心

HOME
CBS 2019
At CBS

General Information

Left Main & Coronary Bifurcation Summit (CBS) was founded in 2006 as a think tank dedicated to the treatment of left main and coronary bifurcation lesions. CBS aims to improve cardiological care by refreshing fundamental researches, clinical trials, yearly published guidelines, emerged ideas and case-based discussion.

Association and Affiliations
- Organized by
  
  Nanjing Heart Center
  
  Asian Bifurcation Club (ABC)
  
  Nanjing First Hospital, Nanjing Medical University
- Co-organized by
  
  Chinese Society of Cardiology (CSC)
  
  Capacity Building and Continuing Education Center,National Health and Family Planning Commission (CBCEC)
  
  American Society for Cardiovascular Angiography and Interventions (SCAI)
  
  Asian Heart Society (AHS)
Contact Us
- Registration Administration of Domestic Representatives
  
  Hongjuan Peng : +86-13913895477
  
  Haimei Xu +86-13914736846
  
  cbsnj@cbsmd.cn
- Registration Administration of Overseas Representatives
  
  Ling Lin : +86 (25) 52271398
  
  +86-13951884596
  
  cbs@cbsmd.cn
- Management of Challenging Cases
  
  Yingying Zhao :+86-13815408517
  
  sub@cbsmd.cn
Address

CBS2019 Congress Secretariat, Nanjing First Hospital, Building No.9 68# Changle Road, Nanjing, China

210006
FACULTY
FACULTY

General Chairman
Congress Chairman
Course Directors International Faculty Domestic Faculty Hong Kong and Taiwan Faculty Members of Academic Committee
Education Center

Education Center

• Online Education (For more customized user interface with self-defined collection of research papers and education resources.)

• CBS Education Resource

• CBSMD Scientific Library
SCIENTIFIC LIBRARY

SCIENTIFIC LIBRARY

Research Paper

> Acute Coronary Syndrom

> ASCVD Prevention

> Bifurcation Stenting

> Cardio-Oncology

> Congestive Heart Failure

> DAPT Duration

> Drug Coated Balloon

> Fractional Flow Reserve

> IVUS Guidance

> Optical Coherence Tomography

> Pulmonary Hypertension

> Rotational Atherectomy

> Shear Stress

> Stenting Left Main

> Transcatheter Aortic Valve Replacement

> Percutaneous LAA Occlusion

> Mitral/Tricuspid Valvular Disease

> Other Relevant Articles

Recommended Paper

Management of Acute Myocardial Infarction During the COVID-19 Pandemic

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19)

< >

HOME | SCIENTIFIC LIBRARY | DAPT Duration

DAPT Duration

Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) Individualized antiplatelet therapy after drug-eluting stent deployment: Implication of clinical trials of different durations of dual antiplatelet therapy

Sort by hits |<<... 2 3 4 5 6 7 8 ...>>|

Letter2020 Aug 11;e017109.

JOURNAL：J Am Heart Assoc. Article Link

Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention

JD McClure, JC Ramsay , C Berry et al. Keywords: ACS; DAPT; antiplatelet agent; meta-analysis; PCI

Full Text PDF

>CBS

CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

CBS 2019

CBS 2019 FACULTY

Education Resource

CBSMD Scientific Library